csirt@kutim:~/threat-intel/cve/CVE-2025-20322

Katalog CVE

CVSS 4.3 · Medium EPSS 0,22%

Kerentanan Cross-Site Request Forgery (CSRF) pada splunk, splunk cloud platform. Skor CVSS 3.1 4.3 (Medium) menurut NVD.

Deskripsi (NVD)

In Splunk Enterprise versions below 9.4.3, 9.3.5, 9.2.7, and 9.1.10, and Splunk Cloud Platform versions below 9.3.2411.104, 9.3.2408.113, and 9.2.2406.119, an unauthenticated attacker could send a specially-crafted SPL search command that could trigger a rolling restart in the Search Head Cluster through a Cross-Site Request Forgery (CSRF), potentially leading to a denial of service (DoS).<br><br>The vulnerability requires the attacker to phish the administrator-level victim by tricking them into initiating a request within their browser. The attacker should not be able to exploit the vulnerability at will.<br><br>See [How rolling restart works](https://docs.splunk.com/Documentation/Splunk/9.4.2/DistSearch/RestartSHC) for more information.

Rincian

Terbit di NVD
7 Juli 2025
Terakhir diubah
17 Juni 2026
Status NVD
Analyzed
CVSS 3.1
4.3 (Medium), sumber NVD
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:N/A:L · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-352: Cross-Site Request Forgery (CSRF)
EPSS (30 hari)
0,22% peluang dieksploitasi; lebih tinggi dari 11,5% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
splunk splunk Versi 9.1.0 hingga sebelum 9.1.10
splunk splunk Versi 9.2.0 hingga sebelum 9.2.7
splunk splunk Versi 9.3.0 hingga sebelum 9.3.5
splunk splunk Versi 9.4.0 hingga sebelum 9.4.3
splunk splunk cloud platform Versi 9.2.2406 hingga sebelum 9.2.2406.119
splunk splunk cloud platform Versi 9.3.2408 hingga sebelum 9.3.2408.113
splunk splunk cloud platform Versi 9.3.2411 hingga sebelum 9.3.2411.104

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.